Gottlieb’s New Year’s Wish List: Risk Management Plans Out, Science In

The growing use of risk management plans to mitigate risk in the post-marketing setting presents "potential harm to patients and the practice of medicine," FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb said during a speech on drug safety at the Manhattan Institute in New York Nov. 13